ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 14 USD 4.63% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
ARS Pharmaceuticals Inc?
Write Note

Intrinsic Value

SPRY's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SPRY stock under the Base Case scenario is 15.5 USD. Compared to the current market price of 14 USD, ARS Pharmaceuticals Inc is Undervalued by 10%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SPRY Intrinsic Value
15.5 USD
Undervaluation 10%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ARS Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SPRY cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SPRY?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
ARS Pharmaceuticals Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about ARS Pharmaceuticals Inc

Provide an overview of the primary business activities
of ARS Pharmaceuticals Inc.

What unique competitive advantages
does ARS Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does ARS Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in ARS Pharmaceuticals Inc recently?

Summarize the latest earnings call
of ARS Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ARS Pharmaceuticals Inc.

Provide P/S
for ARS Pharmaceuticals Inc.

Provide P/E
for ARS Pharmaceuticals Inc.

Provide P/OCF
for ARS Pharmaceuticals Inc.

Provide P/FCFE
for ARS Pharmaceuticals Inc.

Provide P/B
for ARS Pharmaceuticals Inc.

Provide EV/S
for ARS Pharmaceuticals Inc.

Provide EV/GP
for ARS Pharmaceuticals Inc.

Provide EV/EBITDA
for ARS Pharmaceuticals Inc.

Provide EV/EBIT
for ARS Pharmaceuticals Inc.

Provide EV/OCF
for ARS Pharmaceuticals Inc.

Provide EV/FCFF
for ARS Pharmaceuticals Inc.

Provide EV/IC
for ARS Pharmaceuticals Inc.

Show me price targets
for ARS Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for ARS Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for ARS Pharmaceuticals Inc?

What are the Net Income projections
for ARS Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for ARS Pharmaceuticals Inc?

What are the EPS projections
for ARS Pharmaceuticals Inc?

How accurate were the past EPS estimates
for ARS Pharmaceuticals Inc?

What are the EBIT projections
for ARS Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for ARS Pharmaceuticals Inc?

Compare the revenue forecasts
for ARS Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ARS Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ARS Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of ARS Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of ARS Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing ARS Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of ARS Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for ARS Pharmaceuticals Inc.

Provide ROE
for ARS Pharmaceuticals Inc.

Provide ROA
for ARS Pharmaceuticals Inc.

Provide ROIC
for ARS Pharmaceuticals Inc.

Provide ROCE
for ARS Pharmaceuticals Inc.

Provide Gross Margin
for ARS Pharmaceuticals Inc.

Provide Operating Margin
for ARS Pharmaceuticals Inc.

Provide Net Margin
for ARS Pharmaceuticals Inc.

Provide FCF Margin
for ARS Pharmaceuticals Inc.

Show all solvency ratios
for ARS Pharmaceuticals Inc.

Provide D/E Ratio
for ARS Pharmaceuticals Inc.

Provide D/A Ratio
for ARS Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for ARS Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for ARS Pharmaceuticals Inc.

Provide Quick Ratio
for ARS Pharmaceuticals Inc.

Provide Current Ratio
for ARS Pharmaceuticals Inc.

Provide Cash Ratio
for ARS Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for ARS Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for ARS Pharmaceuticals Inc?

What is the current Free Cash Flow
of ARS Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for ARS Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ARS Pharmaceuticals Inc

Current Assets 208.8m
Cash & Short-Term Investments 204.6m
Receivables 1.2m
Other Current Assets 2.9m
Non-Current Assets 8.8m
PP&E 935k
Intangibles 7.5m
Other Non-Current Assets 377k
Current Liabilities 16.6m
Accounts Payable 11.7m
Accrued Liabilities 5m
Efficiency

Earnings Waterfall
ARS Pharmaceuticals Inc

Revenue
2.6m USD
Cost of Revenue
-612k USD
Gross Profit
2m USD
Operating Expenses
-62.5m USD
Operating Income
-60.5m USD
Other Expenses
11.4m USD
Net Income
-49.1m USD

Free Cash Flow Analysis
ARS Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SPRY Profitability Score
Profitability Due Diligence

ARS Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROE is Increasing
Positive Gross Profit
24/100
Profitability
Score

ARS Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

SPRY Solvency Score
Solvency Due Diligence

ARS Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

ARS Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SPRY Price Targets Summary
ARS Pharmaceuticals Inc

Wall Street analysts forecast SPRY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRY is 27.88 USD with a low forecast of 26.26 USD and a high forecast of 31.5 USD.

Lowest
Price Target
26.26 USD
88% Upside
Average
Price Target
27.88 USD
99% Upside
Highest
Price Target
31.5 USD
125% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SPRY?

Click here to dive deeper.

Dividends

ARS Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SPRY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SPRY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

SPRY News

Other Videos

Profile

ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.3B USD

Dividend Yield

0%

Description

ARS Pharmaceuticals, Inc. engages in developing neffy™, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. The company is headquartered in San Diego, California and currently employs 90 full-time employees. The company went IPO on 2020-12-04. The firm is developing neffy (previously referred to ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type 1 allergic reactions, including food, medications, and insect bites that could lead to anaphylaxis. The firm has designed and developed neffy to provide injection-like absorption of epinephrine, in a small nasal spray device.

Contact

CALIFORNIA
San Diego
11682 El Camino Real, Suite 120
+18587719307
ars-pharma.com

IPO

2020-12-04

Employees

90

Officers

Founder, President, CEO & Director
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
Co-Founder & Chief Medical Officer
Dr. Sarina Tanimoto M.B.A., M.D.
Chief Legal Officer & Secretary
Mr. Alexander A. Fitzpatrick Esq.
Co-Founder & Chief Science Officer
Dr. Robert Bell Ph.D.
Chief Financial Officer
Ms. Kathleen D. Scott CPA
Chief Operations Officer
Mr. Brian T. Dorsey M.S.
Show More
Senior Vice President of Marketing
Mr. Daniel Relovsky
Executive Vice President of Commercial Strategy
Mr. Harris Kaplan M.B.A.
Chief Commercial Officer
Mr. Eric Karas
Chief Business Officer & Secretary
Mr. Justin Chakma
Show Less

See Also

Discover More
What is the Intrinsic Value of one SPRY stock?

The intrinsic value of one SPRY stock under the Base Case scenario is 15.5 USD.

Is SPRY stock undervalued or overvalued?

Compared to the current market price of 14 USD, ARS Pharmaceuticals Inc is Undervalued by 10%.

Back to Top